Medical Condition News

RSS

Official guidelines for diagnosis, treatment and management of food allergies released

A collaborative, government-led effort to guide and standardize diagnosis, treatment and management of food allergies has resulted in the release of an official set of recommendations for physicians.

10 Dec 2010

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

10 Dec 2010

Process of activating helicopter EMS delays treatment for heart attacks beyond recommended times

Helicopter emergency medical services can be a life saver for patients needing immediate care. But, according to a University of Cincinnati study, the process of activating them often delays treatment beyond recommended times.

10 Dec 2010

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Serodus AS today announced that it has entered into a license agreement with Roche for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367).

10 Dec 2010

Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market

Elekta K.K., a wholly owned subsidiary of Elekta AB, has entered into a sales and marketing agreement with Toshiba Medical Systems Corporation in Japan.

From Elekta 10 Dec 2010

Social activities most promising in prevention of depression among older adults

Interventions focused on social activities significantly decrease depressive symptoms among older adults. This is the results from a recent study.

10 Dec 2010

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested

10 Dec 2010

STENTYS initiates international APPOSITION III self-apposing stent study in AMI patients

STENTYS S.A., which develops innovative stents to treat Acute Myocardial Infarction (AMI), announced today that it has begun the international APPOSITION III study of its self-apposing stent, with 50 patients already enrolled out of a total of 500. The trial primary endpoint is Major Adverse Cardiac Events at 12 months post-procedure.

10 Dec 2010

Access problems for psychiatric patients to Medicaid medication leads to increased hospital, emergency care

Too often, mental health patients have problems accessing or paying for their prescription drugs under Medicaid. The results — longer hospital stays and more emergency room visits — are hard on patients and costly for the entire health care system, a new study finds.

10 Dec 2010

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its RIGS® technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe's efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.

10 Dec 2010

First genetic test on developing risk of Alzheimer's disease and heart attacks

Alzheimer and heart attacks have been found to share common genetic basis. The research leads the way to the first genetic test on developing the risk of the diseases even at a young age. According to Federico Licastro, an immunologist at the University of Bologna who coordinated the study published in the scientific journal, Journal of Alzheimer's Disease, a test is now ready. "They are already selling it in America", he says, citing the case of a private firm in New Mexico (USA) that collaborated on the study. "But the tests could easily be also conducted wherever, using a simple blood test".

10 Dec 2010

Depression treatment may help obese women to lose weight

The new study, which appears in the November/December issue of the journal General Hospital Psychiatry, cites past surveys that show having a body mass index (BMI) of 30 or more — classified as obese — increases a person's risk of depression by 50 percent to 150 percent.

10 Dec 2010

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and The Regents of the University of California, Los Angeles campus, today announced the execution of an exclusive research agreement that will focus on the identification of biological markers of mucosal healing in patients with Inflammatory Bowel Disease (IBD). The research will be led by Dr. Jonathan Braun, Chair of the Department of Pathology and Laboratory Medicine and a professor of molecular and medical pharmacology, UCLA David Geffen School of Medicine.

10 Dec 2010

Simple molecular sensor color test to determine safe fluoride levels

Used in the proper amounts, it can make teeth stronger and aid in the treatment of osteoporosis. When excessive amounts are consumed, however, it can be a killer - a carcinogen that causes bone, lung and bladder cancers. The "it" is fluoride, a common additive in most American communities' drinking water and an ingredient in the vast majority of commercially produced adult toothpastes.

10 Dec 2010

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

10 Dec 2010

Fibrin microthreads support mesenchymal stem cell growth

A research team at Worcester Polytechnic Institute has demonstrated the feasibility of a novel technology that a surgeon could use to deliver stem cells to targeted areas of the body to repair diseased or damaged tissue, including cardiac muscle damaged by a heart attack. The technique involves bundling biopolymer microthreads into biological sutures and seeding the sutures with stem cells. The team has shown that the adult bone-marrow-derived stem cells will multiply while attached to the threads and retain their ability to differentiate and grow into other cell types.

10 Dec 2010

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

A novel strategy of blocking the growth of blood vessels with antibodies should result in improved treatment of cancerous tumors.

10 Dec 2010

People exposed to North Dakota road materials face increase risk of developing mesothelioma

New data shows that people exposed to the mineral erionite found in the gravel of road materials in North Dakota may be at significantly increased risk of developing mesothelioma, a type of lung cancer most often associated with asbestos exposure, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.

10 Dec 2010

Horizon Discovery licenses new human isogenic cell models from Case Western Reserve

With the goal of developing new, more effective and personalized cancer treatments, Horizon Discovery, based in Cambridge, England, has secured from Case Western Reserve University exclusive rights to a panel of new human isogenic cell models developed by the laboratory of Zhenghe Wang, assistant professor of genetics at the university's School of Medicine.

10 Dec 2010

Nuss Procedure safe and effective for chest deformity

Since 1987, when a surgeon at Children's Hospital of The King's Daughters developed a minimally-invasive surgery to correct sunken chest, the procedure has been adopted world-wide as a standard of care and continually refined to increase its effectiveness and safety, according to a paper published in the December issue of the Annals of Surgery.

10 Dec 2010

Medical Condition News

Official guidelines for diagnosis, treatment and management of food allergies released

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

Process of activating helicopter EMS delays treatment for heart attacks beyond recommended times

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market

Social activities most promising in prevention of depression among older adults

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

STENTYS initiates international APPOSITION III self-apposing stent study in AMI patients

Access problems for psychiatric patients to Medicaid medication leads to increased hospital, emergency care

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

First genetic test on developing risk of Alzheimer's disease and heart attacks

Depression treatment may help obese women to lose weight

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

Simple molecular sensor color test to determine safe fluoride levels

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Fibrin microthreads support mesenchymal stem cell growth

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

People exposed to North Dakota road materials face increase risk of developing mesothelioma

Horizon Discovery licenses new human isogenic cell models from Case Western Reserve

Nuss Procedure safe and effective for chest deformity

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News